Aprowell

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aprowell

Property Description
Active ingredient Naproxen Sodium (INN: Naproxen)
Form Oral (Tablet, Capsule, Suspension)
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General purpose Pain relief, inflammation reduction, fever control
Origin Synthetic (Propionic Acid Derivative)

Classification and Composition of Aprowell

Aprowell is a synthetic, single-ingredient medicine classified within the Nonsteroidal Anti-Inflammatory Drug (NSAID) class. Its active compound is Naproxen Sodium, which is chemically defined as a Propionic Acid Derivative. This oral medication is available in several high-level dosage forms, including standard and specialty tablets (such as delayed-release or extended-release), capsules, and an oral suspension.

The formulation strategically incorporates the sodium salt of Naproxen, a feature recognized for its ability to enhance solubility and promote more rapid absorption from the gastrointestinal tract. This characteristic is clinically recognized as a factor for a potentially quicker onset of its analgesic effects. The utility of Naproxen is further established by its status as a therapeutic alternative on lists of essential medicines.

The General Purpose of Naproxen Sodium

The general purpose of Naproxen Sodium is to provide symptomatic management by reducing discomfort associated with inflammation. It primarily exhibits three core, clinically recognized pharmacological properties: an analgesic effect for reducing pain, an anti-inflammatory effect for decreasing swelling and redness, and an antipyretic effect for lowering fever.

This therapeutic profile is achieved through its primary function as a nonselective inhibitor of cyclooxygenase (COX) enzymes. This action limits the synthesis of inflammatory mediators called prostaglandins, thereby delivering the necessary relief that underpins the drug's use for managing general discomfort in adults and certain pediatric populations.

Regulatory References

  1. FDA label for Naproxen Sodium
  2. WHO Essential Medicines List (EML)

What side effects are possible with Aprowell?

Regulatory Classification of Adverse Reactions

Adverse reactions to Naproxen Sodium (Aprowell) are classified by regulatory bodies into frequency categories and System-Organ Classes (SOCs). Common adverse reactions primarily affect the Gastrointestinal and Nervous Systems, including dyspepsia (indigestion), nausea, abdominal pain, headache, and dizziness. Less frequent effects may involve skin disorders, tinnitus, and fluid retention (edema).

Serious Adverse Reactions and Systemic Risks

Official prescribing information includes mandatory warnings highlighting the risk of serious, sometimes fatal, events:

  • Serious Cardiovascular Thrombotic Events: The drug may increase the risk of events such as myocardial infarction (heart attack) and stroke. This risk may occur early in treatment and generally increases with the duration of use and dose level, as documented by the FDA.
  • Serious Gastrointestinal Events: There is an increased risk of bleeding, ulceration, and perforation of the stomach or intestines, which can occur at any time, often without warning symptoms. Older adults face a higher risk for these events.
  • Severe Hypersensitivity Reactions: Rare but severe reactions like anaphylaxis and severe skin conditions, including Stevens-Johnson Syndrome (SJS), are documented, with the highest risk appearing early in the course of therapy.

Population-Specific Safety Constraints

Use is contraindicated for the management of pain immediately before or after Coronary Artery Bypass Graft (CABG) surgery. Use is also contraindicated during the last trimester of pregnancy due to the potential for harm to the fetus, particularly premature closure of the ductus arteriosus. Patients with severe renal or cardiac failure also have specific restrictions.

Overdose and Emergency Response

Overdose and when to seek help

Aprowell (nefopam) is toxic in overdose, with clinical manifestations involving the central nervous system (CNS) and the cardiovascular system. Due to the reported risk of severe complications, immediate emergency medical attention is required if an overdose is suspected or if any severe symptoms occur.

Overdose has resulted in serious clinical outcomes, including multiple reports of fatal overdoses.

Documented Overdose Presentations

Physiological System Documented Manifestations (from official summaries)
Central Nervous System Confusion, agitation, hallucinations, seizures (convulsions), coma.
Cardiovascular System Tachycardia (fast heartbeat), cardiac conduction abnormalities (e.g., heart block), ventricular tachycardia, cardiac arrest, hyperdynamic circulation.
Other Severe Effects Acute renal failure, cerebral edema (brain swelling).

Required Emergency Actions

If you believe you or someone else has taken too much Aprowell, call emergency services immediately.

Treatment for overdose is typically supportive, focusing on managing the life-threatening CNS and cardiovascular complications. The time-critical nature of these symptoms means that immediate emergency intervention is essential to manage potential seizures, cardiac abnormalities, and hyperdynamic circulation. Do not delay seeking help. The risk of serious or fatal outcomes necessitates the highest level of caution and urgent medical response.

Therapeutic Uses of Aprowell

Aprowell (Naproxen Sodium) is commonly used across domains where additional symptomatic support is needed, primarily to provide supportive relief by addressing the symptoms related to inflammatory or irritative states and physical discomfort. It is relevant in clinical settings marked by heightened patient distress or temporary functional strain caused by disruptive symptom manifestations.

This medicine is relevant in conditions characterized by periods of heightened symptoms, including chronic inflammatory disorders such as osteoarthritis and rheumatoid arthritis, as well as acute issues like tendinitis, bursitis and acute gout. It also helps manage episodic pain manifestations like menstrual cramps and common discomforts like headaches and fever. It is commonly used when short-term symptomatic assistance is needed.

“It assists with maintaining functional stability during acute phases and supports patients during episodes of heightened discomfort.”

The primary benefit is that it helps address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load and improving day-to-day comfort.

Quick Fact: Relief for Inflammatory Pain Aprowell is commonly used to help manage the joint stiffness, swelling, and tenderness associated with long-term inflammatory conditions, providing supportive relief that is applied when appropriate during acute flare-ups.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility Rules for Aprowell (Naproxen Sodium)

Regulatory authorities define the eligible patient population for Aprowell based on age, physiological status, allergic history, and underlying health conditions.

Populations Contraindicated

The medicine is strictly prohibited for patients with:

  • Hypersensitivity: Known allergic reactions to naproxen or any other Nonsteroidal Anti-Inflammatory Drug (NSAID), including a history of aspirin-sensitive asthma.
  • Cardiac Surgery: Use in the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Pregnancy (Third Trimester): Use at 30 weeks gestation and later.
  • Severe Organ Failure: Patients with advanced renal disease (e.g., Creatinine Clearance less than 30 mL/min) or severe uncontrolled heart failure.

Conditional and Age-Related Use

Population Group Regulatory Status
Pediatrics (< 2 years) Safety and efficacy not established.
Pediatrics (2 years & older) Approved for specific prescription uses.
Pregnant Women (20–30 weeks) Avoid use unless directed by a health professional.
Geriatric Patients A lower dose should be considered due to increased risk of serious gastrointestinal adverse events.
Hepatic Impairment Lower dose should be considered; monitoring is advised.

Use also requires caution and monitoring in individuals with a history of gastrointestinal ulcers or bleeding, or established cardiovascular risk factors.

What should I know about interactions with other medicines?

Aprowell Interactions with other medicines and products

This section details the officially documented interaction information for Aprowell (Naproxen Sodium) as stated in regulatory prescribing information.

Interaction Classifications (High-Level)

Classification Examples of Interacting Substances Official Concern
Contraindicated Combinations Other NSAIDs (e.g., Ketorolac), Analgesic doses of Aspirin Formal prohibition or strong caution due to elevated GI and renal risk.
Exposure Modification Lithium, Methotrexate, Probenecid Reduced renal clearance, leading to increased plasma levels and potential for toxicity of the co-administered drug.
Pharmacodynamic Risk Anticoagulants (e.g., Warfarin), SSRIs, Corticosteroids Increased additive risk, such as serious gastrointestinal bleeding or hemorrhage.

Interaction-Related Constraints and Procedural Rules

The regulatory label mandates specific restrictions when co-administering Aprowell:

  • Timing Separation: When taken with Low-dose Aspirin for cardioprotection, Naproxen must be administered at least 30 minutes after or at least 8 hours before the immediate-release aspirin dose to avoid interfering with its anti-platelet effect.
  • Antihypertensive Agents: Co-administration with Diuretics, ACE Inhibitors, or ARBs may result in a reduction of their blood pressure-lowering effect and carries a risk of worsening kidney function.
  • Population-Specific Note: The risk and severity of these interactions, particularly those affecting renal function (e.g., with Diuretics or ACE Inhibitors), are officially noted to be increased in elderly patients and those with existing renal impairment.

Mechanism of Action

Enzyme Blockade and Prostaglandin Synthesis

The primary mechanism involves nonselective, reversible inhibition of the Cyclooxygenase (COX-1 and COX-2) enzymes. By competitively blocking the active sites of these enzymes, Aprowell interrupts the conversion of Arachidonic Acid into Prostaglandins ( PGs) and Thromboxanes ( TXs). This molecular action modulates the signal transmission pathways dependent on these lipid mediators.

Modification of Nociceptive and Thermoregulatory Pathways

The resulting decrease in PGs exerts dual effects on key physiological systems. Peripherally, the drug decreases the sensitization of nerve endings (nociceptors), directly modifying nociceptive signal propagation. Centrally, it limits the production of Prostaglandin E2 ( PGE2) in the hypothalamus, which modifies the central thermoregulatory set-point.

Mechanism Speed and Duration

Aprowell utilizes the sodium salt formulation, a characteristic that promotes quicker dissolution and absorption, leading to rapid saturation of the COX enzymes. However, the inhibitory binding is reversible, meaning the physiological effect is maintained only as long as the concentration of the drug is sufficient to continue blocking the target enzymes.

Dosage and Administration Information

Aprowell (Naproxen/Naproxen Sodium) is intended exclusively for oral administration, utilizing the principle of employing the lowest effective dosage for the shortest duration. The dosing schedules differ based on whether the drug is used for chronic management or acute symptoms.

Dosing and Frequency Patterns

For chronic conditions such as osteoarthritis, the total daily dose typically ranges from 500 mg to 1000 mg, generally taken in two divided doses (every 12 hours). Controlled-release tablets, however, are administered once daily. For acute symptoms, such as an acute gout attack, treatment begins with a higher initial dose of 750 mg (Naproxen base), followed by 250 mg every 8 hours until the acute episode subsides.

Administration and Handling Instructions

All oral forms should be taken with a full glass of water, and it is preferable to take the medicine with or after food to aid gastrointestinal tolerance. Specialized dosage forms, such as delayed-release or controlled-release tablets, must be swallowed whole and should not be crushed, broken, or chewed, as this compromises the intended drug release profile. For the oral suspension, the bottle should be shaken gently before use, and a calibrated measuring device must be used to ensure accurate dosing.

Population-Specific Use

For older adults, standard protocols require the use of the lowest effective dose due to altered drug elimination. Similarly, a lower dose must be considered for patients with renal or hepatic impairment. For children over two years of age with juvenile idiopathic arthritis, the total daily dose is calculated by weight and given in two divided doses. If a scheduled dose is missed, it is generally advised to skip the forgotten dose and continue with the regular schedule; a double dose should not be taken to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aprowell (Naproxen Sodium)

This overview describes the landscape of clinical research conducted for Naproxen Sodium, focusing on the types of studies performed and the symptomatic outcomes that were measured, based on official regulatory and peer-reviewed scientific reviews.


Evidence for Use in Chronic Inflammatory Joint Conditions

The research base for conditions like osteoarthritis and rheumatoid arthritis consists primarily of short- to intermediate-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies involved adult populations and examined outcomes related to physical discomfort, such as patient-reported pain severity, and measures reflecting daily functioning. Findings describe patterns observed in the studies over periods generally ranging from four to twelve weeks.

Evidence for Use in Acute Episodic Pain and Localized Inflammation

Research concerning acute episodic pain, such as menstrual cramps or headaches, relies on short, single-dose or very short-course RCTs. These trials examined the speed of symptomatic change and the cumulative change in pain intensity over short intervals. For acute localized inflammation (e.g., tendinitis, bursitis), the research base includes short-term RCTs that monitor outcomes linked to inflammatory states and functional activity level.


Studies in Specific Groups and Research Limitations

Research has explored the use of Aprowell in specific patient groups, including studies in older adult populations and certain pediatric groups (children aged two and older) with juvenile arthritis. Data for long-term outcomes regarding the sustained symptomatic patterns beyond one year remain insufficiently characterized by controlled trials. The central limitation is that follow-up durations were limited in the core efficacy trials, meaning that certainty remains low regarding the durability of effects after treatment stops. Subgroup findings are often uncertain due to small sample sizes.

Key Studies & References

  1. NAPROXEN SODIUM tablet (DailyMed/FDA Label) – Full prescribing information for indications and usage
  2. Drug Therapy - Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Juvenile Idiopathic Arthritis (PRINTO - Pediatric Rheumatology)

Frequently Asked Questions (FAQ)

Common questions about Aprowell (FAQ)


Q: Is Aprowell the same kind of drug as [Specific common alternative]?

Aprowell (Naproxen Sodium) is officially classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). All drugs in this class, including common alternatives like Ibuprofen, share a similar mechanism of action by helping to block certain enzymes. While they belong to the same category, their effects, duration of action in the body, and specific regulatory uses may differ.


Q: Are there any common foods or drinks that interact with Aprowell?

Official drug documents do not typically list specific common foods that interact with Aprowell. However, regulatory guidance advises taking the medicine with or after food, which is intended to aid gastrointestinal tolerance.


Q: Does Aprowell interact with caffeine?

Caffeine is not generally mentioned as a known interaction in regulatory documents. Official drug interaction warnings focus on other prescription medicines, other NSAIDs, anticoagulants, and alcohol.


Q: Is Aprowell a controlled substance?

No, official drug classification documents state that Aprowell (Naproxen Sodium) is not listed as a controlled drug under the U.S. Controlled Substances Act (CSA) schedule.


Q: Are there any known interactions with herbal supplements?

Regulatory information indicates that there is generally insufficient data to confirm whether herbal supplements are safe to take with Aprowell. Regulatory guidance suggests patients inform a healthcare professional about all supplements being used, as they are not tested in the same way as prescription medicines.


Q: How long does Aprowell stay in your system?

The official product information notes that Aprowell has a relatively long half-life, meaning it remains active in the body longer than some other drugs in its class. This characteristic is recognized as a factor influencing how often it is administered, as defined in official prescribing schedules.


Q: Can Aprowell be safely taken with pain relievers like Tylenol or ibuprofen?

Regulatory guidance strictly advises against taking Aprowell with other non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, due to an increased risk of serious side effects, such as gastrointestinal bleeding. However, official information notes that combining Aprowell with paracetamol (acetaminophen) is not among the contraindicated combinations.


Q: Is Aprowell a safe drug?

Official sources define the conditions under which the medicine is to be used cautiously or is strictly prohibited (contraindicated). The regulatory label includes mandatory warnings on serious potential risks, such as cardiovascular events and gastrointestinal bleeding. Official prescribing information mandates the use of the lowest effective dose for the shortest duration.


Q: Does Aprowell have a risk of dependence or withdrawal?

Aprowell is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID) and is not classified as a controlled substance. Official regulatory classifications do not indicate a risk of physical dependence or withdrawal symptoms typically associated with controlled or addictive substances.


Q: What did the main clinical trials for Aprowell study?

The core clinical trials were conducted to establish efficacy for the drug's approved uses. These include symptomatic management for conditions such as rheumatoid arthritis, osteoarthritis, acute gout, and primary dysmenorrhea. Studies measured outcomes related to physical discomfort and functional capacity.


Q: I've heard Aprowell can cause strange dreams, is that true?

Official listings of adverse reactions for this drug sometimes include central nervous system (CNS) effects, such as headache, dizziness, and drowsiness. Specific sleep disturbances, including unusual or strange dreams, are sometimes listed as a rare or infrequent effect in official regulatory documents.


Q: What is the difference between Aprowell and a supplement like St. John's Wort?

Aprowell is a classified medicine (an NSAID), which means it is a fully regulated drug product with legally defined uses approved by regulatory drug agencies. Supplements like St. John's Wort are non-regulated products whose safety and efficacy claims are generally not reviewed or approved by drug agencies.


Q: What is the success rate described in the studies for Aprowell?

Regulatory content rules prohibit us from publishing specific claims about success rates or guaranteeing the effects of medicines. Official evidence is described in terms of patterns observed in the studies related to measured symptomatic outcomes, like pain severity and physical functioning.


Q: Is Aprowell safe to take during pregnancy or while breastfeeding?

Official product information strictly prohibits (contraindicates) the use of Aprowell from 30 weeks gestation onward due to potential harm to the fetus. Regulatory documents state that small amounts of the drug pass into breast milk, and specific use during breastfeeding requires careful consideration.


Q: Are there long-term effects of Aprowell that are still being studied?

Regulatory warnings indicate that the risk of serious cardiovascular and gastrointestinal events is known to increase with the duration of use. Controlled clinical trials focused on the sustained symptomatic effects beyond one year have been noted as being limited or insufficiently characterized.


Q: I heard Aprowell can affect heart rhythm; is this a big concern?

Official warnings primarily focus on the documented risks of serious cardiovascular thrombotic events, which include myocardial infarction (heart attack) and stroke, and the risk of new or worsening heart failure. Official documents do not typically highlight specific concerns related to cardiac rhythm disorders (arrhythmias).


Q: Why does Aprowell need to be taken consistently?

Aprowell works by blocking target enzymes in the body, but this binding is reversible, meaning the drug’s effectiveness will diminish as it is cleared from the body. Therefore, consistency is required to maintain a sufficient concentration to continue blocking the enzymes and sustain the intended effect.


Q: Can Aprowell make you feel tired or sleepy?

Official adverse reaction lists for this medicine often include fatigue and somnolence (drowsiness) as potential less common or uncommon effects related to the central nervous system.


Q: Is Aprowell known to cause weight gain?

Regulatory documents list fluid retention (edema) as a potential infrequent adverse effect. However, they do not generally list weight gain or obesity as a specific, commonly reported adverse reaction.


Q: Does Aprowell affect birth control pills?

Regulatory interaction data typically do not show a known interaction between Aprowell and hormonal birth control pills that affects the contraceptive's efficacy. Official guidance suggests that patients should discuss all medications with a healthcare professional.


Q: Is it normal to feel a little worse when first starting Aprowell?

Regulatory information notes that the highest risk for certain severe adverse reactions, such as severe skin conditions, appears early in the course of therapy. Additionally, common effects like nausea, dizziness, or headache can occur when initiating the medication.


Q: Can Aprowell affect my ability to drive or operate machinery?

Because the drug may cause effects like dizziness, drowsiness, or visual disturbances, regulatory documents caution that the ability to drive or operate machinery may be impaired. Users should be aware of how they react to the medicine.


Q: Does Aprowell affect blood pressure?

Official warnings note that Aprowell may lead to new onset or worsening of existing hypertension (high blood pressure). It may also reduce the blood pressure-lowering effect of certain other antihypertensive agents taken at the same time.


Q: Can Aprowell cause stomach issues or nausea?

Yes, official documents list gastrointestinal issues as common adverse reactions. These include nausea, indigestion (dyspepsia), and abdominal pain. For this reason, administration instructions often suggest taking the medicine with food.


Q: Can Aprowell make my skin more sensitive to the sun?

Official adverse reaction listings for Aprowell include photosensitivity reactions (increased sensitivity to sunlight), as this is a documented type of adverse skin reaction.


Q: Does taking Aprowell affect your mood or personality?

Official adverse reaction lists include common central nervous system effects like headache and dizziness. Less common or rare effects such as cognitive dysfunction, psychosis, or depression have also been noted in regulatory information.


Q: What serious side effects should I be aware of when taking Aprowell?

Official warnings highlight the risk of serious, life-threatening events, which include cardiovascular thrombotic events (like heart attack and stroke) and severe gastrointestinal events (like bleeding, ulceration, or perforation). These risks are part of the regulatory basis for the official statement to use the lowest effective dose for the shortest duration.

How should Aprowell be stored and disposed of?

Aprowell must be stored and handled according to the specific instructions provided in the official regulatory labeling to maintain its quality and potency.

Official Storage and Disposal Requirements

  • Storage Temperature and Protection: The product must be kept within the specific temperature range (e.g., room temperature, refrigerated) defined by stability studies. The container must be kept tightly closed or in its original outer carton to protect the contents from light and/or moisture, as specified in the labeling.
  • In-Use Stability: If the product requires preparation, mixing, or is a multi-dose container, the label defines a maximum time period and specific conditions for its use after the initial opening or preparation.
  • Child Safety: Always store Aprowell out of the sight and reach of children to prevent accidental exposure.
  • Disposal: Unused, unwanted, or expired medicine must be disposed of following government-authorized procedures. These instructions often advise against flushing the medicine down a toilet or sink and may direct the user to drug take-back programs or specific household trash disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aprowell found in:

A-Z Index: